BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 38323175)

  • 21. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma.
    Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H
    J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.
    Lampis S; Raieli S; Montemurro L; Bartolucci D; Amadesi C; Bortolotti S; Angelucci S; Scardovi AL; Nieddu G; Cerisoli L; Paganelli F; Valente S; Fischer M; Martelli AM; Pasquinelli G; Pession A; Hrelia P; Tonelli R
    J Exp Clin Cancer Res; 2022 Apr; 41(1):160. PubMed ID: 35490242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.
    Bartolucci D; Montemurro L; Raieli S; Lampis S; Pession A; Hrelia P; Tonelli R
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell death-based treatment of neuroblastoma.
    Valter K; Zhivotovsky B; Gogvadze V
    Cell Death Dis; 2018 Jan; 9(2):113. PubMed ID: 29371588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions.
    Zheng M; Kumar A; Sharma V; Behl T; Sehgal A; Wal P; Shinde NV; Kawaduji BS; Kapoor A; Anwer MK; Gulati M; Shen B; Singla RK; Bungau SG
    Front Cell Dev Biol; 2024; 12():1353860. PubMed ID: 38601081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of PIF1, a potential new target of MYCN, induces apoptosis and inhibits cell migration in neuroblastoma cells.
    Chen B; Hua Z; Gong B; Tan X; Zhang S; Li Q; Chen Y; Zhang J; Li Z
    Life Sci; 2020 Sep; 256():117820. PubMed ID: 32512012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation.
    Le Clorennec C; Lee K; Huo Y; Zage PE
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Murine neuroblastoma cell lines developed by conditional reprogramming preserve heterogeneous phenotypes observed in vivo.
    Krawczyk E; Hong SH; Galli S; Trinh E; Wietlisbach L; Misiukiewicz SF; Tilan JU; Chen YS; Schlegel R; Kitlinska J
    Lab Invest; 2020 Jan; 100(1):38-51. PubMed ID: 31409888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches.
    Bottino C; Dondero A; Bellora F; Moretta L; Locatelli F; Pistoia V; Moretta A; Castriconi R
    Front Immunol; 2014; 5():56. PubMed ID: 24575100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.
    Andolfo I; Lasorsa VA; Manna F; Rosato BE; Formicola D; Iolascon A; Capasso M
    J Cell Mol Med; 2020 Jun; 24(11):6459-6471. PubMed ID: 32336043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells.
    Wang J; Gu S; Huang J; Chen S; Zhang Z; Xu M
    BMC Cancer; 2014 Oct; 14():768. PubMed ID: 25323222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Ki-67 as prognostic factor for pediatric neuroblastoma and the possibility of molecular-targeted drugs with VEGF and PDGFR.
    Watanabe S; Suzuki T; Kondo Y; Naoe A; Uga N; Yasui T; Hara F; Tsuchiya T
    Minerva Pediatr (Torino); 2023 Aug; 75(4):561-566. PubMed ID: 30605998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroblastoma: paradigm for precision medicine.
    Irwin MS; Park JR
    Pediatr Clin North Am; 2015 Feb; 62(1):225-56. PubMed ID: 25435121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exosomes from Plasma of Neuroblastoma Patients Contain Doublestranded DNA Reflecting the Mutational Status of Parental Tumor Cells.
    Degli Esposti C; Iadarola B; Maestri S; Beltrami C; Lavezzari D; Morini M; De Marco P; Erminio G; Garaventa A; Zara F; Delledonne M; Ognibene M; Pezzolo A
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33915956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
    Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
    Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma.
    Yan H; Zhai B; Yang F; Chen Z; Zhou Q; Paiva-Santos AC; Yuan Z; Zhou Y
    Front Pharmacol; 2022; 13():908713. PubMed ID: 35721107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings.
    Decock A; Ongenaert M; Vandesompele J; Speleman F
    Epigenetics; 2011 Aug; 6(8):962-70. PubMed ID: 21725203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in the developmental origin of neuroblastoma: an overview.
    Ponzoni M; Bachetti T; Corrias MV; Brignole C; Pastorino F; Calarco E; Bensa V; Giusto E; Ceccherini I; Perri P
    J Exp Clin Cancer Res; 2022 Mar; 41(1):92. PubMed ID: 35277192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.